NCT00607230View on ClinicalTrials.gov

Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

February 28, 2011

Conditions
Type 1 Diabetes Mellitus
Interventions
BIOLOGICAL

BCG

BCG vaccination at 0 and 4 weeks

BIOLOGICAL

Saline

Saline vaccination at 0 and 4 weeks

Trial Locations (1)

02114

Diabetes Research Center at Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT00607230 - Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics | Biotech Hunter | Biotech Hunter